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Abstract
Objectives—The goal of this study was to include the quantitation of hexacosanoyl 
lysophosphatidylcholine, a biomarker for X-linked adrenoleukodystrophy and other peroxisomal 
disorders, in the routine extraction and analysis procedure used to quantitate amino acids, 
acylcarnitines, and succinylacetone during newborn screening. Criteria for the method included 
use of a single punch from a dried blood spot, one simple extraction of the punch, no high-
performance liquid chromatography, and utilizing tandem mass spectrometry to quantitate the 
analytes.
Design and methods—Dried blood spot punches were extracted with a methanolic solution of 
stable-isotope labeled internal standards, formic acid, and hydrazine, followed by flow injection 
analysis–electrospray ionization–tandem mass spectrometry.
Results—Quantitation of amino acids, acylcarnitines, and hexacosanoyl lysophosphatidylcholine 
using this combined method was similar to results obtained using two separate methods.
Conclusions—A single dried blood spot punch extracted by a rapid (45 min), simple procedure 
can be analyzed with high throughput (2 min per sample) to quantitate amino acids, acylcarnitines, 
succinylacetone, and hexacosanoyl lysophosphatidylcholine.
Keywords
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linked adrenoleukodystrophy
1. Introduction
Newborn screening (NBS)1 utilizes the analysis of dried blood spot (DBS) extracts for 
biomarkers [e.g. amino acids (AA) and acylcarnitines (AC)] that indicate an inborn error of 
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metabolism when they are outside normal limits (elevated or deficient) [1]. Early detection, 
diagnosis, and treatment of inborn errors of metabolism prevent disability and death [2]. 
Flow injection analysis–electrospray ionization–tandem mass spectrometry (FIA–ESI–
MS/MS) is the most widely used method to quantitate AA and AC in DBS extracts because 
it is rapid, sensitive, specific, and easily multiplexed for 20 to 30 analytes of interest and 
their corresponding stable-isotope labeled internal standards used for quantitation [3–5].
A variety of DBS extraction procedures have been published and/or incorporated into 
commercial products [5–7]. Criteria for a widely applicable procedure include simplicity, 
rapidity, avoiding expensive or hazardous reagents, and the ability to extract biomarkers with 
a variety of chemical properties [e.g. AA, AC, succinylacetone (SUAC), and lipids] from the 
DBS punch. Some methods derivatize AA, AC, and SUAC to form butyl esters [8] while 
other methods do not [9]. A hydrazine derivatization of SUAC is commonly used to improve 
its positive-mode ionization efficiency [5].
We describe a DBS extraction (without derivatization to form butyl esters) and FIA–ESI–
MS/MS analytical method which incorporates quantitation of hexacosanyl 
lysophosphatidylcholine (C26:0-LPC) into routine analysis of AA, AC, and SUAC. C26:0-
LPC is a biomarker for X-linked adrenoleukodystrophy (X-ALD) [10] and other 
peroxisomal biogenesis disorders (PBD). It has previously been analyzed by FIA–ESI–
MS/MS [11] and high-performance liquid chromatography–ESI–MS/MS (HPLC–ESI–MS/
MS), both of which typically require a second punch from the newborn's DBS sample, a 
separate extraction protocol, and a separate analysis with respect to AA–AC–SUAC 
quantitation [12–14]. We used the method described here to quantitate AA, AC, SUAC, and 
C26:0-LPC in quality control DBS specimens produced at the Centers for Disease Control 
and Prevention's (CDC) Newborn Screening Quality Assurance Program (NSQAP). These 
quality control DBSs were prepared from human blood enriched with AA, AC, and SUAC 
followed by homogeneity testing and characterization of AA, AC, and SUAC quantities via 
20 independent measurements [15]. The analyte enrichment of human blood utilized 
commercially available standards prepared as stock solutions (in water or methanol) and 
their concentrations were verified by comparison of diluted analyte peak areas to 
commercially available stable-isotope labeled AA, AC, and SUAC. Our results indicated that 
the recoveries of AA, AC, and C26:0-LPC were similar to the results obtained from two 
separate methods (AA–AC–SUAC [5] and C26:0-LPC [14]), and that the quantitation of 
SUAC was slightly less sensitive than NSQAP's in-house AA–AC–SUAC method. 
Anonymous residual DBS specimens from presumed normal newborns (N = 151) were 
assayed to determine the mean and 95% confidence interval of C26:0-LPC, and to confirm 
that AA, AC, and SUAC quantitation was similar to aggregate NBS data from the Region 4 
Stork MS/MS Collaborative (R4S) [4,16]. In addition, analysis of DBS specimens from 
confirmed cases (N = 28) of single-enzyme defect (SED), D-bifunctional protein deficiency 
lysophosphatidylcholine), X-ALD (X-linked adrenoleukodystrophy), PBD (peroxisomal biogenesis disorder), HPLC–ESI–MS/MS 
(high performance liquid chromatography–electrospray ionization–tandem mass spectrometry), NSQAP (Newborn Screening Quality 
Assurance Program), SED (single-enzyme defect), DBP (D-bifunctional protein deficiency), MRM (multiple reaction monitoring), 
R4S (Region IV Stork MS/MS Collaborative Project).
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(DBP) and PBD/Zellweger spectrum disorder showed C26:0-LPC concentrations higher 
than the 95% confidence interval for presumed normal newborns in every case.
2. Materials and methods
2.1. Reagents
D4-C26:0-LPC was from Avanti Polar Lipids (Alabaster, AL), and stable-isotope labeled 
AA, AC, and SUAC were from Cambridge Isotopes (Tewksbury, MA). HPLC-MS grade 
water, methanol, and formic acid were from Fisher Scientific (Pittsburg, PA). Hydrazine 
hydrate was from Sigma-Aldrich (St. Louis, MO).
2.2. Dried blood spots
Two specimens were quality control materials enriched with AA, AC, and SUAC (1432 and 
1434), three specimens were quality control materials enriched with C26:0-LPC (13104, 
13105, and 13106), seven specimens were calibrators enriched with SUAC (Cal A to Cal G), 
151 specimens were anonymous residual newborn screening punches (NBS 1 to NBS 151), 
and 28 specimens were from confirmed cases of SED, DBP, and PBD. All punches were 3 
mm (1/8″). The blood used to prepare the quality control and calibrator specimens was 
hematocrit adjusted to 50 ± 1% and either lysed by freeze-thawing (1432, 1434, 13104, 
13105, and 13106) or used with intact red-blood cells (SUAC calibrators). Lysed blood DBS 
were 100 μL each and intact blood DBS were 75 μL each; all NSQAP DBS were prepared 
on Whatman 903 paper, dried overnight, and stored at –20 °C with low (<30%) humidity. 
The anonymous, residual NBS DBS were stored at –20 °C with low (<30%) humidity for 29 
months before analysis, and the confirmed peroxisomal disorder DBS were stored at –20 °C 
with low (<30%) humidity for 7 years before analysis.
2.3. Internal standards
A stock solution of 13C5-succinylacetone (1 mg/mL) was prepared in water, aliquoted, and 
stored at –70 °C; 79.6 μL of this stock was added to 200 mL of methanol for a final 
concentration of 2.5 μM. A stock solution of D4-C26:0-LPC (1 mg/mL) was prepared in 
methanol and stored at 4 °C; 184.4 μL of this stock was added to the same 200 mL of 
methanol for a final concentration of 0.2 μM. One vial each of NSK-A, NSK-B, and NSK-
BG was solubilized according to the manufacturer's instructions and added to the 200 mL of 
methanol for final concentrations of 2.5 μM [phenylalanine (Phe), leucine (Leu), methionine 
(Met), tyrosine (Tyr), valine (Val), citrulline (Cit), arginine (Arg), and alanine (Ala)], 0.76 
μM [free carnitine (C0)], 0.04 μM [acetylcarnitine (C2), propionylcarnitine (C3), 
butyrylcarnitine (C4), isovalerylcarnitine (C5), hydroxyisovalerylcarnitine (C5OH), 
octanoylcarnitine (C8), glutarylcarnitine (C5DC), dodecanoylcarnitine (C12), and 
tetradecanoylcarnitine (C14)], and 0.08 μM [palmitoylcarnitine (C16) and 
octadecanoylcarnitine (C18)]. The internal standard solution also contained 100 μL (0.05%) 
formic acid and 30 μL hydrazine hydrate (2.7 mM hydrazine) in order to derivatize SUAC to 
a hydrazone and improve its positive ion mode peak intensity. The internal standard solution 
was stored at 4 °C, allowed to warm to room temperature before use, and discarded after 10 
days.
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Each DBS punch (3 mm) was placed in a well of a polypropylene 96-well plate (VWR, 
Suwannee, GA), 100 μL of the methanolic internal standard solution was added to each well, 
the plate was heat-sealed with foil (BioSero, San Diego, CA), and extracted for 45 min at 
45 °C with shaking in a covered incubator (Thermo Scientific, Waltham, MA). After 
extraction the liquid contents of each well were transferred to a new 96-well plate followed 
by heat-sealing and FIA–ESI–MS/MS analysis.
2.5. Flow-injection analysis by electrospray ionization tandem mass spectrometry
An Agilent 1290 liquid chromatography system was used with an Applied Biosystems 
API-4000 triple quadrupole mass spectrometer to analyze the DBS punch extracts in positive 
ion mode. Turbo V ion source conditions were curtain gas = 20, gas 1 = 30, gas 2 = 10, 
electrospray capillary voltage = 5.5 kV, and temperature = ambient. The collision gas setting 
was 5. Each sample injection was 10 μL. The mobile phase was methanol containing 0.02% 
formic acid, and the mobile phase flow rate was reduced during each analysis to increase the 
residence time of analytes in the ion source, thereby improving the number of scans with 
high signal-to-noise obtained per injection. Specifically, the flow rate was 100 μL per min at 
sample injection, slowed to 18 μL per minute between 0.1 and 1.1 min, increased to 400 μL 
per min between 1.1 and 1.5 min, and returned to 100 μL per min between 1.5 and 2.0 min. 
The mass spectrometer acquired data between 0 and 2 min by performing 5 experiments: 1) 
multiple reaction monitoring (MRM) for C0, C2, C3, and their internal standards, 2) 
precursor ion scanning from m/z 215 to 475 for precursors of m/z 85.0 (C3 to C18OH AC's), 
3) neutral loss scanning from m/z 74 to 220 for neutral loss of 46.0 Da (non-basic AA's), 4) 
MRM for Arg, Cit, SUAC, and their internal standards, and 5) MRM for C26:0-LPC and its 
internal standard. The MRM transitions used in the 5th experiment were 636.5 → 104.1 
(C26:0-LPC) and 640.5 → 104.1 (D4-C26:0-LPC). Supplementary Table 1 shows scan 
parameters for all analytes.
2.6. Data processing
The data files from Analyst (1.5.1) were processed by ChemoView (Applied Biosystems, 
Foster City CA). The concentration of each analyte was calculated using the formula:
(analyte peak area, cps) / (internal standard peak area, cps) × [internal standard, μM] × 
dilution factor.
Dilution factor was 32.26, which represents the volume of the extraction solution (100 μL) 
divided by the volume of whole blood at 50% hematocrit in a 3 mm punch (3.1 μL [17]).
3. Results
3.1. Quality control materials for amino acids, acylcarnitines, and succinylacetone
The quantitative results of analysis by the method described here were compared to the 
results of NSQAP's in-house AA–AC–SUAC analysis [5]. Table 1 shows the mean and 95% 
confidence interval for these analytes as measured by the two methods using NSQAP's 
quality control specimen enriched with low concentrations of analytes (1432). Table 2 shows 
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the comparison of the two methods using NSQAP's quality control specimen enriched with 
high concentrations of analytes (1434). In both specimens the results of the two methods 
were similar with the exception of SUAC.
3.2. Succinylacetone calibrators
Fig. 1 shows a comparison of SUAC quantitation using NSQAP's in-house AA–AC–SUAC 
method and the method described here. Seven specimens with increasing concentrations of 
enriched SUAC were analyzed and linear regression was used to determine the apparent 
recovery based upon the slope of a scatter plot of enrichments vs. measurements. The in-
house method and the method described here resulted in 47% and 28% apparent recovery of 
SUAC, respectively.
3.3. Quality control materials for hexacosanoyl lysophosphatidylcholine
The quantitative results of analysis by the method described here were compared to the 
results of NSQAP's in-house HPLC analysis [14]. Fig. 2 shows the mean and standard 
deviation for C26:0-LPC as measured by the two methods using NSQAP's quality control 
specimens with zero (13104), 1 μmol/L (13105), and 10 μmol/L (13106) enrichments of this 
analyte. The zero enrichment specimen (13104) had a very low measured concentration 
when analyzed by HPLC–ESI–MS/MS in negative ion mode (0.03 μM) but a higher 
measured concentration when analyzed by FIA–ESI–MS/MS in positive ion mode (0.7 μM). 
This result is consistent with previously reports of an isobaric compound in human blood 
that is observed in positive ion mode but not negative ion mode [12,14,18]. Enrichment with 
C26:0-LPC was additive with the value measured in specimen 13014, with 100% apparent 
recovery in the low enrichment specimen (1.7 μM) and 96% apparent recovery in the high 
enrichment specimen (10.3 μM).
3.4. Anonymous residual newborn screening specimens
Punches of anonymous, residual presumed normal NBS DBS were analyzed by the method 
described here and the results were compared to the 50th percentile of a normal population 
(Region IV Stork MS/MS Collaborative Project [4]). Table 3 shows that AA, AC, and SUAC 
analytes had average concentrations similar to the aggregate data from R4S, and that the 
95% confidence intervals included all 50th percentile values from R4S.
3.5. Confirmed cases of peroxisomal disorders
Anonymous, residual DBS specimens from patients with SED, DBP, and PBD (N = 28) 
were analyzed and the results are shown in Fig. 3. The specimens were from patients of 
different ages [<1 month (8), < 6 months (4), <1 year (4), <5 years (5), <10 years (5), and 
N10 years (4)]; all DBS had been collected between 2005 and 2007. In every case the 
measured C26:0-LPC quantities were greater than the 95% upper confidence limit observed 
in presumed normal newborns (see Section 3.4).
4. Discussion
Inclusion of a new analyte in an existing multiplex FIA–ESI–MS/MS method must 
demonstrate that no (or a minor) reduction in sensitivity has occurred for the existing 
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analytes (Tables 1 and 2), and that the apparent recovery of the new analyte is acceptable 
(Fig. 2). The only analyte with significantly reduced apparent recovery when comparing the 
in-house NSQAP method and the method described here was SUAC, which showed a 
reduction from 47% to 28% (Fig. 1). This reduction does not preclude the utility of SUAC as 
a biomarker for Tyrosinemia Type I, as several methods currently used in NBS programs 
show SUAC recovery of approximately 30% [19]. Laboratories engaged in NBS can use 
SUAC calibrators to correct their raw data, or set their cut-off between normal and outside 
normal limits lower as potential solutions to less-than-100% apparent recovery. It should 
also be noted that the in-house NSQAP method shows one of the highest apparent recoveries 
of SUAC among published and commercially available methods [19].
As previously reported [12,18], the presence of a compound isobaric with C26:0-LPC when 
using positive ion mode quantitation did increase the (apparent) concentration of this analyte 
in zero enrichment quality control DBS from 0.03 to 0.7 μM (Fig. 2); however, enrichment 
of the low and high quality control DBS specimens was additive with the value measured in 
the zero enrichment specimen, resulting in 100% apparent recovery with a 1 μM enrichment. 
It was of interest that the average concentration of the isobaric compound in presumed 
normal newborns (0.4 μmol/L) was lower than the average concentration in quality control 
materials prepared from freeze-thawed pooled adult red-blood cells and serum (0.7 μmol/L).
Comparison of the mean and 95% confidence limits for AA, AC, and SUAC quantitation in 
presumed normal newborns to cumulative averages from the R4S MS/MS Collaborative 
Project (Table 3) indicated the suitability of the method described here for those analytes, 
and comparison of C26:0-LPC quantitation in presumed normal newborns to specimens 
from confirmed cases of peroxisomal disorders (Fig. 3) indicated elevation of C26:0-LPC 
outside normal limits in every case. The elevation of C26:0-LPC in affected newborns [12] 
and the absence of false positives in a large sample of newborns [10] have been previously 
described.
In summary, the use of a methanolic extraction solution containing stable-isotope labeled 
internal standards for AA, AC, SUAC, and C26:0-LPC combined with positive ion mode 
FIA–ESI–MS/MS analysis shows apparent recovery for these analytes from DBS punches 
that is similar to results obtained with separate AA–AC–SUAC and C26:0-LPC methods. 
This increases throughput (one analysis vs. two), reduces labor (one extraction vs. two), and 
allows for C26:0-LPC quantitation during newborn screening of DBS extracts.
Supplementary Material
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Comparison of succinylacetone calibrators quantitated using the in-house CDC method 
(solid line) and the method including hexacosanoyl lysophosphatidylcholine (dotted line). 
Apparent recovery was 47% (N = 2 on each of 10 days) for the in-house method and was 
28% (N = 3 on each of 3 days) for the method described here. Calibrators were enriched 
with 0, 1.5, 3, 5, 10, 20, and 50 μmol/L succinylacetone.
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Comparison of FIA– and HPLC–ESI–MS/MS analyses of quality control materials enriched 
with C26:0-LPC. Specimens 13104, 13105, and 13106 with C26:0-LPC enrichments of 0, 1, 
and 10 μmol/L, respectively, were assayed using the FIA–ESI–MS/MS method described 
here (open circles) and by the CDC's in-house HPLC–ESI–MS/MS method (solid circles). 
Error bars represent the standard deviation (N = 40). Comparing linear regression of the FIA 
method (dashed line) to that of the HPLC method (solid line) indicated a higher y-intercept 
(0.73 μmol/L) for the latter.
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Measured concentrations of C26:0-LPC in DBS punches from presumed normal newborns 
and patients. The average of presumed normal newborn samples (N = 151) is shown (open 
circle) in comparison to 3 confirmed cases of single-enzyme defect (open triangles), 4 
confirmed cases of D-bifunctional protein deficiency (open squares) and 21 confirmed cases 
of peroxisomal biogenesis disorder/Zellweger spectrum disorder (filled circles). The 95% 
confidence interval for presumed normal newborns (mean ± 1.96 × standard deviation) was 
0.2 to 0.6 μmol/L whole blood (dashed lines). The lowest C26:0-LPC measured in a patient 
was 0.69 μmol/L whole blood (specimen #25).
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Table 1
Comparison of amino acid, acylcarnitine, and succinylacetone quantitation in quality control dried blood spots 






c Mean, μM 95% C.I., μM Mean, μM 95% C.I., μM
Phe 100 139.2 116.1-162.2 146.5 124.0-169.0
Leu 100 198.8 170.6-227.1 195.6 140.7-250.4
Met 50 53.1 41.4-64.9 61.5 51.0-72.0
Tyr 200 182.7 143.8-221.7 203.4 165.6-241.1
Val 200 283.2 232.8-333.7 291.7 241.2-342.1
Cit 25 32.3 25.5-39.1 35.3 29.6-41.1
Arg 100 107.2 73.8-140.6 110.2 90.0-130.4
Ala 200 385.6 286.4-484.8 430.9 325.7-536.2
SUAC 2.5 1.4 1.2-1.7 1.1 0.8-1.4
C0 10 20.1 17.0-23.2 17.7 15.1-20.3
C2 10 21.1 18.0-24.1 20.7 17.5-23.8
C3 3 3.7 2.6-4.7 3.9 3.2-4.6
C4 1 0.9 0.7-1.2 0.9 0.7-1.1
C3DC + C4OH 1 0.3 0.2-0.4 0.3 0.2-0.4
C5 0.5 0.5 0.4-0.7 0.5 0.4-0.6
C5OH 0.5 1.1 0.8-1.4 1.3 0.9-1.7
C5DC 0.5 0.6 0.4-0.9 0.6 0.4-0.8
C6 0.5 0.5 0.3-0.6 0.5 0.4-0.6
C8 0.5 0.5 0.4-0.7 0.5 0.4-0.7
C10 0.5 0.6 0.4-0.8 0.6 0.4-0.8
C12 0.5 0.5 0.3-0.6 0.5 0.4-0.6
C14 0.5 0.5 0.4-0.7 0.5 0.4-0.6
C16 3 3.1 2.3-3.8 3.2 2.4-3.9
C16OH 0.1 0.1 0.0-0.1 0.1 0.0-0.1
C18 1 1.5 0.9-2.0 1.6 1.2-2.0
C18OH 0.5 0.2 0.1-0.4 0.3 0.2-0.3
C26:0-LPC NA NA NA 0.3 0.2-0.4
aResults of N = 2 punches on each of 20 days, method of Dhillon, et al.
bResults of N = 6 punches on each of 7 days, method described in this paper.
cEnrichment does not include endogenous analytes in the human blood matrix.
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Table 2
Comparison of amino acid, acylcarnitine, and succinylacetone quantitation in quality control dried blood spots 






c Mean, μM 95% C.I., μM Mean, μM 95% C.I., μM
Phe 300 314.2 262.2-366.2 343.6 301.4-385.8
Leu 500 437.7 361.0-514.4 447.3 347.4-547.2
Met 250 183.9 152.7-215.1 233.8 199.2-268.5
Tyr 600 473.4 385.3-561.5 548.9 466.9-630.9
Val 500 487.0 399.5-574.6 540.7 480.1-601.2
Cit 250 198.4 161.7-235.2 236.3 204.6-268.0
Arg 300 306.9 232.5-381.4 320.7 256.3-385.2
Ala 600 612.4 502.6-722.1 694.1 542.0-846.3
SUAC 15 8.9 6.8-11.0 6.7 5.7-7.7
C0 30 36.2 30.7-41.8 35.1 31.0-39.1
C2 30 40.3 34.1-46.5 42.7 37.9-47.5
C3 12 11.3 8.7-13.9 12.7 10.5-14.9
C4 5 4.2 3.2-5.3 4.5 3.7-5.4
C3DC + C4OH 5.5 1.1 0.8-1.3 1.3 1.0-1.5
C5 3 2.7 2.0-3.4 2.9 2.3-3.4
C5OH 2.5 2.9 2.1-3.6 3.6 2.8-4.4
C5DC 2.5 2.6 1.7-3.4 2.5 1.9-3.0
C6 2.5 2.1 1.6-2.6 2.5 2.0-2.9
C8 2.5 2.4 1.8-2.9 2.6 2.1-3.2
C10 2.5 2.5 1.9-3.1 2.6 2.0-3.1
C12 2.5 2.0 1.5-2.6 2.5 2.0-2.9
C14 3 2.7 2.0-3.4 2.7 2.2-3.3
C16 12 9.5 7.7-11.3 10.5 8.8-12.1
C16OH 1 0.5 0.3-0.7 0.5 0.4-0.7
C18 5 4.6 3.6-5.6 5.3 4.4-6.3
C18OH 1.5 0.7 0.3-1.1 0.8 0.6-1.0
C26:0-LPC NA NA NA 0.3 0.2-0.4
aResults of N = 2 punches on each of 20 different days, method of Dhillon, et al.
bResults of N = 6 punches on each of 7 different days, method described in this paper.
cEnrichment does not include endogenous analytes in the human blood matrix.
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Table 3
Amino acid, acylcarnitine, succinylacetone, and hexacosanoyl lysophosphatidylcholine quantitation in 
anonymous residual newborn screening specimens (N = 151).
Method including C26:0-LPC Region IV Stork (R4S) Data
Analyte Median, μM Mean,| M 95% C.I., μM
a Normal population 50th %
Phe 60.8 63.0 32.0-94.0 49
Leu 75.0 79.4 29.4-129.4 127
Met 12.4 13.3 4.9-21.8 20
Tyr 83.9 89.0 30.8-147.2 83
Val 103.3 109.2 51.9-166.4 108
Cit 12.5 12.7 7.0-18.4 12.2
Arg 9.8 11.6 0.0-24.9 8.5
Ala 237.2 246.8 108.0-385.6 223
SUAC 0.9 0.9 0.6-1.1 0.6
C0 17.1 18.4 5.7-31.1 22
C2 15.7 15.8 4.2-27.4 21
C3 1.5 1.6 0.3-3.0 1.7
C4 0.1 0.2 0.0-0.5 0.2
C3DC + C4OH 0.2 0.1 0.0-0.2 0.1
C5 0.1 0.1 0.0-0.3 0.1
C5OH 0.3 0.3 0.1-0.5 0.2
C5DC 0.2 0.2 0.0-0.3 0.1
C6 0.1 0.1 0.0-0.1 0.1
C8 0.1 0.1 0.0-0.2 0.1
C10 0.1 0.2 0.0-0.3 0.1
C12 0.1 0.1 0.0-0.2 0.1
C14 0.2 0.2 0.1-0.3 0.2
C16 2.4 2.5 1.0-4.1 2.7
C16OH 0.0 0.04 0.0-0.1 0.02
C18 0.9 0.9 0.4-1.4 0.8
C18OH 0.03 0.04 0.0-0.1 0.01
C26:0-LPC 0.4 0.4 0.2-0.6 NA
aThe 95% confidence interval is from (mean – 1.96 × standard deviation) to (mean + 1.96 × standard deviation).
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